Gulamhusein Aziz, Mangera Altaf
Department of Urology Research, Sheffield Teaching Hospitals NHS Trust, Royal Hallamshire Hospital, Sheffield, United Kingdom.
Biologics. 2012;6:299-306. doi: 10.2147/BTT.S30180. Epub 2012 Aug 28.
This review examines the evidence for use of onabotulinumtoxinA in the treatment of neurogenic lower urinary tract dysfunction. Since its first use in 1988 to treat detrusor sphincter dyssynergia, use of botulinum toxin has increased in this group of patients. We discuss the mechanism of action, patient selection, dosing, efficacy, and side effect profile of this now licensed treatment option.
本综述探讨了使用A型肉毒毒素治疗神经源性下尿路功能障碍的证据。自1988年首次用于治疗逼尿肌括约肌协同失调以来,肉毒毒素在这类患者中的应用有所增加。我们讨论了这种现已获得许可的治疗方法的作用机制、患者选择、剂量、疗效和副作用情况。